Coenzyme Q in cardiovascular disease

Journal of Association of Physicians of India

Volumn 46, Issue 3, 1998, Pages 299-306

  Singh, R B ^a   Niaz, M A ^a   Rastogi, V ^a   Rastogi, S S ^a  

^a Medical Hospital and Research Centre Moradabad   (India)

Author keywords

[No Author keywords available]

Indexed keywords

UBIQUINONE;

ANIMAL; CARDIOVASCULAR DISEASE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; UBIQUINONE;

EID: 0032008962     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Greenberg S, Frishman WH. Coenzyme Q10. A new drug for cardiovascular disease. J Clin Pharmacol 1990; 30 : 596-608.
2. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochimica Biophys Acta 1995; 1271 : 195-204.
3. Folkers K, Yamagam T, eds Biomedical and clinical aspects of coenzyme Q, Vol 6, Amisterdam Elservier. 1991.
4. Kagan V, Packer L. Electron transport regenerates vitamin E in mitochondria and microsomes via ubiquinone, an antioxidant duet In. Corongni F, Banni S, Desai MA, Rice Evans C, eds. Free radicals and antioxidants and nutrition, London. Richelieu Press 1993; 27-36.
5. Stoeker R, Bowry WV, Frei B. Uhiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA 1991; 88: 1646-50.
6. Merati G, Pasquali P, Vergani C, Landi L. Antioxidant activity of ubiquinone-3 in human low density lipoprotein. Free Rad Res Commun 1992; 16 : 11-7.
7. Mohr D, Bowry VW, Stocker R. Dietary supplementation with CoQ10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low density lipoprotein to the initiation of lipid peroxidation, Biochim Biophys Acta 1992; 1126 : 247-54.
8. Esconde D, Cavero I. Potassium channel openers, moving towards cardioprotection via strengthening of a natural mechanism. Trends Pharmacal Sci 1992; 13 : 269-72.
9. Grech ED, Jackson M, Ramsdale DR. Reperfusion injury after acute myocardial infarction. Br Med J 1995; 310 : 10 477-78.
10. Singh RB, Niaz MA. Antioxidants, oxidant and free radical stress in cardiovascular disease. J Asso Phy India 1996; 44 : 43-8.
11. Qndarroa M, Quinn P. Proton magnetic resonance spectroscopic studies of the interaction of ubiquinone-10 with phospholipid membranes. Int J Biochem 1986; 155 : 353-8.
12. Niki E. Chemistry and biochemistry of vitamin E and coenzyme Q as antioxidants. in Corongiu F, Banni S, Dessi MA Z, Rice-Evans C eds. Free radicals and antioxidants in nutrition. London, Ricehelieu Press 1993; 13-25.
13. Langsjoen PH, Vadhanavikit S, Folkers K. Effective treatment with coenzyme Q10 of patients with myocardial disease classes III and IV. In Folkers K, Yamamura Y, eds. Biomedical, clinical aspects of coenzyme Q vol 4 Amsterdam Elsevier 1984; 325-39.
14. Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamasaki N. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985; 56 : 247-51.
15. Schardr F, Welzer D, Schess W, Toda K. Effect of coenzyme Q10 on ischaemia-induced ST-segment depression a double blind placebo controlled crossover study. In : Folkers K, Yamamura Y, eds Biomedical and clinical aspects of coenzyme Q10, Vol 5 Amsterdam Elsevier 1986; 385-94.
16. Mazzola C, Guffanti EE, Vaccarella A, et al. Noninvasive assessment of coenzyme Q10 in patients with chronic stable effort angina and moderate heart failure. Curr Ther Res 1987; 41: 923-30.
17. Rosi E, Lombardo A, Testa M, et al. Coenzyme Q10 in ischaemic cardiopathy. In Folkers K, Littarru GP, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q. Vol 6 Astherdam Elsevier 1991; 321-6.
18. Wilson MF, Frishman WH, Giles T, sethi G, Greenberg SM, Brackett DJ. Coenzyme Q10 therapy and exercise duration in stable angina. In : Folkers K, Littami GP, Yamogami T, eds. Biomedical and clinical aspects of coenzyme Q Vol 6 Amsterdam Elserier 1991; 339-48.
19. Bresolin N, Moroni I, Angilini C, et al. Ubiquinone treatment in patients with mitochondrial myopathies the first double blind trial. In : Folkers K, Litame GP, Yamagami Teds. Biochemical and Clinical aspects of coenzyme Q Vol 6. Amsterdam Elservier 1991; 397-405.
20. Ursini F, Gambini C, Paciaroni E, Littarni GP. Coenzyme Q10 treatment of heart failure in elderly preliminary results. In : Folkers K, Littarru GP, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q Vol 6. Amsterdam Elsevier 1991; 473-80.
21. Hofman-Bang C, Rehnqvist N, Swedberg K, Astrom H. Coenzyme Q10 as an adjunctive in treatment of congestive heart failure J Am Coll Cardiol 1992; 19 (Suppl): 774-76.
22. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure a long term multicentre randomized study. Clin Invest 1993; 71 (Suppl): 134-36.
23. Mortensen SA, Vadhanavikit S, Folkers K. Apparent effectiveness of coenzyme Q10 (CoQ) to treat patients with cardiomyopathy and CoQ levels in blood and endomyocardial biopsies. In Folkers K, Yamamura Y eds. Biomedical and clinical aspects of coenzyme Q. Vol 4. Amsterdam Elsevier 1984; 391-402.
24. Permanetter B, Rossy W, Weingartner F, Baner R, Seidi KF, Klein G, Fehlende Wirksamkeit von coenzyme Q10 (Ubiquinone) bei langzeitbehandlung der dilatativen Kardiomyopathie. Z Kardiol 1989; 78 : 360-65.
25. Judy WV, Folkers K, Hall JH. Improved long-term survival in coenzyme Q10 treated congestive heart failure patients compared to conventionally treated eds. Biomedical and clinical aspects of coenzyme Q. Vol 6 Amsterdam Elsevier 1991; 291-8.
26. Chatterjee K. Heart failure therapy in evolution. Circulation 1996; 94 : 2689-93.
27. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996; 28 : 506-14.
28. Judy WV, Stogsdill WW, Folkers K. Myocardial preservation bytherapy with coenzyme Q10 during heart surgery. Clin Invest 1993; 71 (Suppl): 155-61.
29. Takasawa K, Fuse K, Konishi T, Watanable Y. Prevention of premature ventricular contractions with CoQ10 after coronary artery bypass grafting. In Folkers K, Littarru GP, Yamagami T eds. Biomedical and clinical Aspects of Coenzyme Q Vol 6 Amsterdam Elsevier 1991; 357-9.
30. Fihirdi B, Vsnyini G, Oradei A, et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994; 15(Suppl) : 265-83.
31. Langsjoen P, Wills R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994; 15(Suppl): 265-72.
32. Iarussi D, Auricchio U, Murano A, et al. Protective effect of coenzyme Q on anthracyclines cardiotoxicity control study in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma, Mol Aspects Med 1994; 15 (Suppl): 207-12.
33. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10 lowering effect by HMGCoA reductase enhibitor a double blind placebo controlled J Clin Pharmacol 1993; 33 : 226-9.
34. Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 1994; 24 : 171-6.
35. Singh RB, Singh NK, Rastogi SS, et al. Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovas Drug Ther 1997 (in press).